{
  "ticker": "PER",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02962342",
  "id": "02962342",
  "pages": 6,
  "price_sensitive": true,
  "date": "20250626",
  "time": "1018",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250626/pdf/06l45lq41076qw.pdf",
  "summary": "**Material Information Summary:**  \n\n- **License Agreement:** Exclusive worldwide license for HMBD-002 (phase II-ready monoclonal antibody targeting VISTA) acquired from Hummingbird Bioscience.  \n- **Financial Terms:**  \n  - Upfront payment: **US$3M (AU$4.6M)**.  \n  - Potential milestones: **up to US$287M (AU$443M)** plus **12.5% tiered royalties** on net sales.  \n- **Clinical Status:** Phase I trial completed (safety/pharmacological activity confirmed); phase II trials targeted for **CY2026**.  \n- **Strategic Impact:** Transforms Percheron into a mid-clinical-stage oncology developer; replaces discontinued avicursen (DMD) program.  \n\n**Omitted:** Background on immuno-oncology/VISTA, CEO commentary, operational FAQs (no material financial/regulatory triggers).",
  "usage": {
    "prompt_tokens": 3263,
    "completion_tokens": 188,
    "total_tokens": 3451,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-26T00:48:20.050575"
}